Table 1.
Clinical trials of M7824.
| NCT number | Cancer type | Phase | Primary Measure Outcomes | Status |
|---|---|---|---|---|
| NCT03833661 | Biliary tract cancer, Cholangiocarcinoma, Gallbladder cancer | 2 | ORR | Completed |
| NCT03524170 | Breast cancer | 1 | Safety | Completed |
| NCT03840915 | NSCLC | 1/2 | Safety | Completed |
| NCT02699515 | Solid tumors | 1 | Safety | Completed |
| NCT04066491 | Biliary tract cancer, Cholangiocarcinoma, Gallbladder cancer | 2/3 | Safety and OS | Completed |
| NCT02517398 | Solid tumors | 1 | Safety | Completed |
| NCT04489940 | TNBC | 2 | ORR | Completed |
| NCT04246489 | Uterine cervical neoplasms | 2 | ORR | Completed |
| NCT04220775 | HNSCC | 1/2 | Safety and PFS | Completed |
| NCT04551950 | Cervical cancer | 1 | Safety | Completed |
| NCT04501094 | Urothelial cancer | 2 | ORR | Terminated |
| NCT03840902 | NSCLC | 2 | PFS | Terminated |
| NCT03451773 | Pancreatic cancer | 1/2 | Safety and ORR | Terminated |
| NCT04327986 | Pancreatic cancer | 1/2 | PR2D, Safety, and ORR | Terminated |
| NCT04560686 | NSCLC | 2 | ORR | Terminated |
| NCT04428047 | HNSCC | 2 | ORR | Terminated |
| NCT04727541 | Cholangiocarcinoma | 2 | ORR | Terminated |
| NCT04971187 | NSCLC | 2 | ORR and PFS | Terminated |
| NCT04417660 | Thymic cancer | 2 | ORR | Recruiting |
| NCT05005429 | Mesothelioma and lung cancer | 2 | PFS | Recruiting |
| NCT04303117 | Kaposi sarcoma | 1/2 | Safety | Recruiting |
| NCT04432597 | HPV+ cancer | 1/2 | Safety, PR2D, and CD3+ TIL | Recruiting |
| NCT03554473 | SCLC | 1/2 | ORR | Recruiting |
| NCT03493945 | Prostate cancer | 1/2 | Clinical benefit | Recruiting |
| NCT05012098 | Olfactory neuroblastoma | 2 | ORR | Recruiting |
| NCT03315871 | Prostate cancer | 2 | PSA | Recruiting |
| NCT04708470 | Solid tumors | 1/2 | ORR and PR2D | Recruiting |
| NCT03427411 | Solid tumors | 2 | ORR | Active, not recruiting |
| NCT03631706 | NSCLC | 3 | PFS and OS | Active, not recruiting |
| NCT03436563 | Colorectal cancer, MSI-H solid tumors | 1/2 | ORR, ctDNA | Active, not recruiting |
| NCT05061823 | Lung cancer | 3 | Safety | Active, not recruiting |
| NCT04247282 | Head and neck cancer | 1/2 | ORR | Active, not recruiting |
| NCT04574583 | Solid tumors | 1/2 | ORR | Active, not recruiting |
| NCT04491955 | Small bowel cancer, colorectal cancer | 2 | ORR | Active, not recruiting |
| NCT04287868 | Solid tumors | 1/2 | ORR | Active, not recruiting |
| NCT04789668 | Solid tumors | 1/2 | ORR, PR2D, Safety, and OS | Active, not recruiting |
| NCT04396535 | NSCLC | 2 | PFS | Active, not recruiting |
ORR, objective response rate; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; TNBC, triple negative breast cancer; OS, overall survival; HNSCC, head and neck squamous cell carcinoma; PFS, progression-free survival; PR2D, recommended phase II dose; TIL, tumor-infiltrating lymphocyte; MSI-H, microsatellite instability-high; ctDNA, circulating tumor DNA.